This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Simulations Plus (SLP) Releases GastroPlus™ 8.0

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 8.0 of its flagship GastroPlus™ simulation software with significantly expanded functionality and user convenience.

GastroPlus 8.0 now includes:
  • Simulation of both inhibition and induction of transporters and enzymes in any tissue using the physiologically based pharmacokinetics (PBPK) model, and simulations of drug-drug interactions based on any combination of such actions
  • Ability to specify dissolution rates as function of pH, including fitting “Z Factor” from multiple in vitro dissolution experiments at different pH
  • Enhanced modeling of drug absorption and distribution for ocular and pulmonary delivery
  • Addition of a paracellular permeability model that specifically accounts for movement of drug between the epithelial cells lining the intestinal wall, in addition to transport into and through the cells
  • Enhanced PDPlus™ module for building pharmacodynamics (drug effect) models and predicting pharmacodynamic effects for new doses and dosage forms
  • An expanded library of animal physiologies
  • Expanded outputs for the Population Simulator
  • Increased execution speed
  • Numerous user convenience features and “sanity checks” to prevent users from running simulations with inputs that appear to be inconsistent

Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, “Version 8.0 represents a major upgrade of our industry-leading GastroPlus software for the simulation of drug absorption, pharmacokinetics, and pharmacodynamics. It incorporates changes involving several person-years of effort since our last major release of Version 7.0 in August 2010. These changes are a combination of features requested by industry scientists and of our own design that extend the power of GastroPlus in important ways for analysis of both preclinical and clinical data.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,824.55 +104.63 0.59%
S&P 500 2,094.02 +13.61 0.65%
NASDAQ 5,138.8820 +30.2160 0.59%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs